NorthCrest Asset Manangement LLC Purchases Shares of 2,809 STERIS plc $STE

NorthCrest Asset Manangement LLC acquired a new position in STERIS plc (NYSE:STE) during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund acquired 2,809 shares of the medical equipment provider’s stock, valued at approximately $678,000.

Other institutional investors also recently bought and sold shares of the company. Steigerwald Gordon & Koch Inc. purchased a new position in STERIS in the 3rd quarter worth approximately $25,000. Spurstone Advisory Services LLC bought a new position in shares of STERIS in the second quarter worth approximately $29,000. Geneos Wealth Management Inc. increased its stake in shares of STERIS by 416.0% in the first quarter. Geneos Wealth Management Inc. now owns 129 shares of the medical equipment provider’s stock worth $29,000 after buying an additional 104 shares during the period. TruNorth Capital Management LLC purchased a new position in shares of STERIS in the third quarter worth $37,000. Finally, NBT Bank N A NY bought a new stake in STERIS during the 3rd quarter valued at $41,000. 94.69% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at STERIS

In other news, VP John Adam Zangerle sold 15,000 shares of the firm’s stock in a transaction that occurred on Tuesday, November 11th. The stock was sold at an average price of $265.14, for a total value of $3,977,100.00. Following the completion of the transaction, the vice president owned 33,669 shares in the company, valued at $8,926,998.66. This trade represents a 30.82% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, VP Julia Madsen sold 5,008 shares of the company’s stock in a transaction on Friday, November 21st. The stock was sold at an average price of $262.00, for a total value of $1,312,096.00. Following the completion of the sale, the vice president directly owned 10,710 shares in the company, valued at approximately $2,806,020. The trade was a 31.86% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 25,044 shares of company stock valued at $6,586,218. Corporate insiders own 1.07% of the company’s stock.

STERIS Stock Performance

Shares of STE stock opened at $261.16 on Thursday. The firm has a market capitalization of $25.63 billion, a price-to-earnings ratio of 37.52 and a beta of 1.03. The stock has a fifty day moving average of $258.82 and a 200 day moving average of $247.19. STERIS plc has a 52 week low of $204.90 and a 52 week high of $269.44. The company has a quick ratio of 1.63, a current ratio of 2.37 and a debt-to-equity ratio of 0.27.

STERIS (NYSE:STE) last issued its quarterly earnings data on Wednesday, November 5th. The medical equipment provider reported $2.47 EPS for the quarter, topping the consensus estimate of $2.38 by $0.09. STERIS had a net margin of 12.07% and a return on equity of 14.43%. The business had revenue of $1.46 billion during the quarter, compared to analyst estimates of $1.43 billion. During the same period in the prior year, the business earned $2.14 EPS. STERIS has set its FY 2026 guidance at 10.150-10.30 EPS. As a group, research analysts expect that STERIS plc will post 9.08 earnings per share for the current year.

STERIS Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Thursday, December 18th. Shareholders of record on Tuesday, November 18th were issued a dividend of $0.63 per share. The ex-dividend date was Tuesday, November 18th. This represents a $2.52 dividend on an annualized basis and a dividend yield of 1.0%. STERIS’s dividend payout ratio is 36.21%.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “buy (b)” rating on shares of STERIS in a report on Friday, January 9th. Seven analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $273.50.

STERIS Profile

STERIS Corporation (NYSE: STE) is a global provider of infection prevention, contamination control and procedural products and services for the healthcare, life sciences, pharmaceutical and medical device industries. The company develops, manufactures and supports a broad portfolio of equipment and consumables designed to reduce risk of infection, maintain sterile environments and support critical clinical and manufacturing procedures.

Its offerings include sterilization and decontamination systems, instrument washers and washers-disinfectors, endoscope reprocessing solutions, surgical equipment and procedural disposables, and contamination-control products for cleanrooms and laboratories.